Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239


THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA.

Flint AC, Faigeles BS, Cullen SP, Kamel H, Rao VA, Gupta R, Smith WS, Bath PM, Donnan GA; VISTA Collaboration.

Stroke. 2013 Dec;44(12):3365-9. doi: 10.1161/STROKEAHA.113.002794. Epub 2013 Sep 26.


The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.

Flint AC, Gupta R, Smith WS, Kamel H, Faigeles BS, Cullen SP, Rao VA, Bath PM, Wahlgren N, Ahmed N, Donnan GA; SITS International and VISTA-plus investigators.

Int J Stroke. 2014 Aug;9(6):705-10. doi: 10.1111/ijs.12335. Epub 2014 Jul 15.


The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.

Kamel H, Patel N, Rao VA, Cullen SP, Faigeles BS, Smith WS, Flint AC.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1111-6. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.017. Epub 2012 Nov 2.


THRIVE score predicts outcomes with a third-generation endovascular stroke treatment device in the TREVO-2 trial.

Flint AC, Xiang B, Gupta R, Nogueira RG, Lutsep HL, Jovin TG, Albers GW, Liebeskind DS, Sanossian N, Smith WS; TREVO-2 Trialists.

Stroke. 2013 Dec;44(12):3370-5. doi: 10.1161/STROKEAHA.113.002796. Epub 2013 Sep 26.


Predicting clinical outcomes after thrombolysis using the iScore: results from the Virtual International Stroke Trials Archive.

Saposnik G, Reeves MJ, Johnston SC, Bath PM, Ovbiagele B; VISTA Collaboration.

Stroke. 2013 Oct;44(10):2755-9. doi: 10.1161/STROKEAHA.113.001343. Epub 2013 Jul 25.


The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.

Saposnik G, Demchuk A, Tu JV, Johnston SC; Stroke Outcomes Research Canada (SORCan) Working Group.

J Stroke Cerebrovasc Dis. 2013 Aug;22(6):876-82. doi: 10.1016/j.jstrokecerebrovasdis.2012.09.001. Epub 2012 Oct 24.


The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke.

Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, Johnston SC; Investigators of the Registry of the Canadian Stroke Network (RCSN); Stroke Outcomes Research Canada (SORCan) Working Group.

Stroke. 2012 May;43(5):1315-22. doi: 10.1161/STROKEAHA.111.646265. Epub 2012 Feb 3.


Improved ischemic stroke outcome prediction using model estimation of outcome probability: the THRIVE-c calculation.

Flint AC, Rao VA, Chan SL, Cullen SP, Faigeles BS, Smith WS, Bath PM, Wahlgren N, Ahmed N, Donnan GA, Johnston SC; SITS International and VISTA-plus investigators.

Int J Stroke. 2015 Aug;10(6):815-21. doi: 10.1111/ijs.12529. Epub 2015 Jun 4.


Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.

Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, Sandercock P; IST-3 Collaborative Group.

Stroke. 2014 Apr;45(4):1000-6. doi: 10.1161/STROKEAHA.113.004362. Epub 2014 Mar 6.


The THRIVE score strongly predicts outcomes in patients treated with the Solitaire device in the SWIFT and STAR trials.

Flint AC, Cullen SP, Rao VA, Faigeles BS, Pereira VM, Levy EI, Jovin TG, Liebeskind DS, Nogueira RG, Jahan R, Saver JL; SWIFT and STAR trialists.

Int J Stroke. 2014 Aug;9(6):698-704. doi: 10.1111/ijs.12292. Epub 2014 May 20.


The iScore predicts clinical response to tissue plasminogen activator in Korean stroke patients.

Park TH, Park SS, Ko Y, Lee SJ, Lee KB, Lee J, Kang K, Park JM, Choi JC, Kim DE, Cho YJ, Hong KS, Kim JT, Kim DH, Cha JK, Han MK, Lee JS, Lee J, Yu KH, Lee BC, Yoon BW, Bae HJ, Saposnik G.

J Stroke Cerebrovasc Dis. 2014 Feb;23(2):367-73. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.025. Epub 2013 Jun 22.


Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Scott PA, Frederiksen SM, Kalbfleisch JD, Xu Z, Meurer WJ, Caveney AF, Sandretto A, Holden AB, Haan MN, Hoeffner EG, Ansari SA, Lambert DP, Jaggi M, Barsan WG, Silbergleit R.

Acad Emerg Med. 2010 Oct;17(10):1062-71. doi: 10.1111/j.1553-2712.2010.00868.x.


Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.

Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, Ikeda Y, Matsuura T, Narai H, Omori N, Manabe Y, Yunoki T, Takao Y, Kawata S, Kashihara K, Abe K.

J Stroke Cerebrovasc Dis. 2013 Apr;22(3):190-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.016. Epub 2011 Oct 2.


Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.

Mehta RH, Cox M, Smith EE, Xian Y, Bhatt DL, Fonarow GC, Peterson ED; Get With The Guidelines-Stroke Program.

Stroke. 2014 Aug;45(8):2263-9. doi: 10.1161/STROKEAHA.114.005019. Epub 2014 Jun 24.


Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.

Li M, Wang-Qin RQ, Wang YL, Liu LB, Pan YS, Liao XL, Wang YJ, Xu AD.

J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1235-43. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.026. Epub 2015 Apr 16.


Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage.

Gumbinger C, Gruschka P, Böttinger M, Heerlein K, Barrows R, Hacke W, Ringleb P.

Stroke. 2012 Jan;43(1):240-2. doi: 10.1161/STROKEAHA.111.623033. Epub 2011 Oct 13.


Posttreatment variables improve outcome prediction after intra-arterial therapy for acute ischemic stroke.

Prabhakaran S, Jovin TG, Tayal AH, Hussain MS, Nguyen TN, Sheth KN, Terry JB, Nogueira RG, Horev A, Gandhi D, Wisco D, Glenn BA, Ludwig B, Clemmons PF, Cronin CA, Tian M, Liebeskind D, Zaidat OO, Castonguay AC, Martin C, Mueller-Kronast N, English JD, Linfante I, Malisch TW, Gupta R.

Cerebrovasc Dis. 2014;37(5):356-63. doi: 10.1159/000362591. Epub 2014 Jun 18.


Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).

Charidimou A, Pasi M, Fiorelli M, Shams S, von Kummer R, Pantoni L, Rost N.

Stroke. 2016 Sep;47(9):2364-72. doi: 10.1161/STROKEAHA.116.014096. Epub 2016 Aug 4. Erratum in: Stroke. 2016 Oct;47(10):e244.


Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.

Merkler AE, Salehi Omran S, Gialdini G, Lerario MP, Yaghi S, Elkind MSV, Navi BB.

Stroke. 2017 Aug;48(8):2282-2284. doi: 10.1161/STROKEAHA.117.018119. Epub 2017 Jul 5.


Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?

Lee SH, Kim BJ, Han MK, Park TH, Lee KB, Lee BC, Yu KH, Oh MS, Cha JK, Kim DH, Nah HW, Lee J, Lee SJ, Ko Y, Kim JG, Park JM, Kang K, Cho YJ, Hong KS, Choi JC, Kim JT, Choi K, Kim DE, Ryu WS, Kim WJ, Shin DI, Yeo M, Lee J, Lee JS, Gorelick PB, Bae HJ.

Int J Stroke. 2016 Oct;11(7):783-90. doi: 10.1177/1747493016654289. Epub 2016 Jun 16.


Supplemental Content

Support Center